药学学报, 2019, 54(7): 1317-1324
引用本文:
卢加琪, 韦薇, 刘伯宁, 罗建辉. 间充质干细胞的研究进展与药学评价[J]. 药学学报, 2019, 54(7): 1317-1324.
LU Jia-qi, WEI Wei, LIU Bo-ning, LUO Jian-hui. Research progress, chemistry, manufacturing and controls considerations of mesenchymal stem cell products[J]. Acta Pharmaceutica Sinica, 2019, 54(7): 1317-1324.

间充质干细胞的研究进展与药学评价
卢加琪, 韦薇, 刘伯宁, 罗建辉
国家药品监督管理局药品审评中心, 北京 100022
摘要:
截至2018年12月,世界范围内有900余个间充质干细胞(mesenchymal stem/stromal cell,MSC)研究项目正在开展或完成了临床研究,其数量一直占据各类干细胞疗法临床试验数量的第1位。近年来国内多个间充质干细胞产品开展了非注册临床研究,并开始按照药品申报临床试验。科学界对间充质干细胞的生物学功能及临床治疗效果在不断认知积累中,其体外培养观测到的功能受到体内实际生存环境的限制未能充分显现。不同组织来源间充质干细胞的培养方法、传代代次、细胞表型和功能均有差异,且制剂工艺、临床给药方式和剂量也显著影响临床疗效。间充质干细胞的体外培养条件、诱导方式与回输人体后微环境的差异性,使产品中的细胞难以保持分离前的原始状态。因此,间充质干细胞的来源、制备工艺和复杂性、多样性、变异性等特点,及其存在争议的定义和功能,也给按照药品审评审批带来了挑战。本文综述了国内外间充质干细胞的药物研发进展和临床研究现状,讨论了间充质干细胞的生产原材料、生产工艺、质量研究等药学评价要点,以期为国内间充质干细胞产品的药学评价提供参考。
关键词:    间充质干细胞      临床研究      生产工艺      质量控制      药学评价     
Research progress, chemistry, manufacturing and controls considerations of mesenchymal stem cell products
LU Jia-qi, WEI Wei, LIU Bo-ning, LUO Jian-hui
Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
Abstract:
The number of clinical trials for mesenchymal stem cell (MSC) products ranked the top among all stem cell products, with more than 900 trials ongoing or completed by 2018. In China, many MSC clinical trials have started as "the third type of medical technique" and the dossiers of MSC products have been submitted to National Medical Products Administration (NMPA). The biological function and therapeutic effect of MSCs are constantly being recognized in scientific communities. However, the observed functions of MSCs in vitro are not fully reproduced in the living microenvironment in vivo. There are substantial variations among tissue origins, cellular phenotypes and biological functions. Different formulations, delivery methods, manufacture processes or doses all greatly affect the clinical efficacy. It is difficult for MSCs to maintain the naive state due to the differences between in vitro culture conditions and in vivo microenvironment. Meanwhile, there is no widely accepted scientific definition for MSCs until now, due to the complexity of manufacturing process and variable sources. Consequently, the regulation of MSC products is a challenge for drug administrative agencies. In this article, we review the research progress of MSC products around the world, and summarize the considerations in evaluating the chemistry, manufacturing and controls (CMC) section of MSC product applications, with respect to raw materials, manufacture processes and quality control. We hope that the information summarized here will provide insights for the development and evaluation of MSC products.
Key words:    mesenchymal stem cell    clinical research    manufacture process    quality control    chemistry, manufacture and control evaluation   
收稿日期: 2019-02-23
DOI: 10.16438/j.0513-4870.2019-0135
通讯作者: 罗建辉,Tel:86-10-85243072,E-mail:luojh@cde.org.cn
Email: luojh@cde.org.cn
相关功能
PDF(559KB) Free
打印本文
0
作者相关文章
卢加琪  在本刊中的所有文章
韦薇  在本刊中的所有文章
刘伯宁  在本刊中的所有文章
罗建辉  在本刊中的所有文章

参考文献:
[1] Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC:the international society for cellular therapy position statement[J]. Cytotherapy, 2005, 7:393-395.
[2] Keating A. Mesenchymal stromal cells:new directions[J]. Cell Stem Cell, 2012, 10:709-716.
[3] Horwitz E, Keating A,Nonhematopoietic Mesenchymal Stem Cell Committee Report. Nonhematopoietic mesenchymal stem cells:what are they?[J]. Cytotherapy, 2000, 2:387-388.
[4] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8:315-317.
[5] Galipeau J, Sensébé L. Mesenchymal stromal cells:clinical challenges and therapeutic opportunities[J]. Cell Stem Cell, 2018, 22:824-833.
[6] Friedenstein A, Petrakova K, Kurolesova A, et al. Heterotopic transplants of bone marrow[J]. Transplantation, 1968, 6:230-247.
[7] Caplan AI. Mesenchymal stem cells[J]. J Orthop Res, 1991, 9:641-650.
[8] Via AG, Frizziero A, Oliva F. Biological properties of mesenchymal stem cells from different sources[J]. Muscles Ligaments Tendons J, 2012, 2:154-162.
[9] Sacchetti B, Funari A, Remoli C, et al. No identical "mesenchymal stem cells" at different times and sites:human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels[J]. Stem Cell Rep, 2016, 6:897-913.
[10] Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells):implications for therapeutic use[J]. Bone Marrow Transpl, 1995, 16:557-564.
[11] Jossen V, Van Den Bos C, Eibl R, et al. Manufacturing human mesenchymal stem cells at clinical scale:process and regulatory challenges[J]. Appl Microbiol Biotechnol, 2018, 102:3981-3994.
[12] Lu JQ, Liu BN, Luo JH. Research progress and regulatory perspectives for stem cell-based regenerative medicine products[J]. Sci Sin Vitae (中国科学:生命科学), 2019, 49:18-27.
[13] Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS):a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Neurol, 2017, 16:360-368.
[14] Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease:a phase 3 randomised, double-blind controlled trial[J]. Lancet, 2016, 388:1281-1290.
[15] Teerlink JR, Metra M, Filippatos GS, et al. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling:results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study[J]. Eur J Heart Fail, 2017, 19:1520-1529.
[16] Bharti D, Shivakumar SB, Park JK, et al. Comparative analysis of human Wharton's jelly mesenchymal stem cells derived from different parts of the same umbilical cord[J]. Cell Tissue Res, 2018, 372:51-65.
[17] Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells-current trends and future prospective[J]. Biosci Rep, 2015, 35:e0091.
[18] Colter DC, Class RF, Digirolamo CM, et al. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow[J]. Proc Natl Acad Sci USA, 2000, 97:3213-3218.
[19] Shahdadfar A, Frønsdal K, Haug T, et al. In vitro expansion of human mesenchymal stem cells:choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability[J]. Stem Cells, 2005, 23:1357-1366.
[20] Chamberlain G, Fox J, Ashton B, et al. Concise review:mesenchymal stem cells:their phenotype, differentiation capacity, immunological features, and potential for homing[J]. Stem Cells, 2007, 25:2739-2749.
[21] Wuchter P, Bieback K, Schrezenmeier H, et al. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications[J]. Cytotherapy, 2015, 17:128-139.
[22] Codinach M, Blanco M, Ortega I, et al. Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells[J]. Cytotherapy, 2016, 18:1197-1208.
[23] Sekiya I, Larson BL, Smith JR, et al. Expansion of human adult stem cells from bone marrow stroma:conditions that maximize the yields of early progenitors and evaluate their quality[J]. Stem Cells, 2002, 20:530-541.
[24] Tormin A, Li O, Brune JC, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization[J]. Blood, 2011, 117:5067-5077.
[25] Bonab MM, Alimoghaddam K, Talebian F, et al. Aging of mesenchymal stem cell in vitro[J]. BMC Cell Biol, 2006, 7:14.
[26] Røsland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation[J]. Cancer Res, 2009, 69:5331-5339.
[27] Göbel C, Goetzke R, Eggermann T, et al. Interrupted reprogramming into induced pluripotent stem cells does not rejuvenate human mesenchymal stromal cells[J]. Sci Rep, 2018, 8:11676.
[28] Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells[J]. Stem Cells, 2007, 25:371-379.
[29] Barkholt L, Flory E, Jekerle V, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints[J]. Cytotherapy, 2013, 15:753-759.
[30] Mirabel C, Puente-Massaguer E, Del Mazo-Barbara A, et al. Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products[J]. J Trans Med, 2018, 16:291.
[31] Thirumala S, Zvonic S, Floyd E, et al. Effect of various freezing parameters on the immediate post-thaw membrane integrity of adipose tissue derived adult stem cells[J]. Biotechnol Prog, 2005, 21:1511-1524.
[32] Moll G, Alm JJ, Davies LC, et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?[J]. Stem Cells, 2014, 32:2430-2442.
[33] Vaculik C, Schuster C, Bauer W, et al. Human dermis harbors distinct mesenchymal stromal cell subsets[J]. J Invest Dermatol, 2012, 132:563-574.
[34] Zhang XH, Hirai M, Cantero S, et al. Isolation and characterization of mesenchymal stem cells from human umbilical cord blood:reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue[J]. J Cell Biochem, 2011, 112:1206-1218.
[35] Park JC, Kim JM, Jung IH, et al. Isolation and characterization of human periodontal ligament (PDL) stem cells (PDLSCs) from the inflamed PDL tissue:in vitro and in vivo evaluations[J]. J Clin Periodontol, 2011, 38:721-731.
[36] Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs[J]. Cell Stem Cell, 2008, 3:301-313.
[37] Bieback K, Kinzebach S, Karagianni M. Translating research into clinical scale manufacturing of mesenchymal stromal cells[J]. Stem Cells Int, 2011, 2010:193519.
[38] Lee WC, Shi H, Poon Z, et al. Multivariate biophysical markers predictive of mesenchymal stromal cell multipotency[J]. Proc Natl Acad Sci USA, 2014, 111:E4409-E4418.
[39] Klopp AH, Gupta A, Spaeth E, et al. Concise review:dissecting a discrepancy in the literature:do mesenchymal stem cells support or suppress tumor growth?[J]. Stem Cells, 2011, 29:11-19.
[40] Sensebé L, Tarte K, Galipeau J, et al. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells[J]. Cell Stem Cell, 2012, 10:9-10.
[41] Tarte K, Gaillard J, Lataillade JJ, et al. Clinical-grade production of human mesenchymal stromal cells:occurrence of aneuploidy without transformation[J]. Blood, 2010, 115:1549-1553.
[42] Mendicino M, Bailey AM, Wonnacott K, et al. MSC-based product characterization for clinical trials:an FDA perspective[J]. Cell Stem Cell, 2014, 14:141-145.
[43] Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials[J]. Cytotherapy, 2016, 18:151-159.
[44] Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche[J]. Nature, 2010, 466:829-834.
[45] Bianco P. "Mesenchymal" stem cells[J]. Annu Rev Cell Dev Biol, 2014, 30:677-704.
[46] Krampera M, Galipeau J, Shi YF, et al. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal[J]. Cytotherapy, 2013, 15:1054-1061.
[47] Chinnadurai R, Rajan D, Qayed M, et al. Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach[J]. Cell Rep, 2018, 22:2504-2517.
[48] Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation[J]. Sci Transl Med, 2017. DOI:10.1126/scitranslmed.aam7828.
[49] Bari E, Perteghella S, Di Silvestre D, et al. Pilot production of mesenchymal stem/stromal freeze-dried secretome for cell-free regenerative nanomedicine:a validated GMP-compliant process[J]. Cells, 2018. DOI:10.3390/cells7110190.
[50] Codispoti B, Marrelli M, Paduano F, et al. NANOmetric BIO-Banked MSC-Derived Exosome (NANOBIOME) as a novel approach to regenerative medicine[J]. J Clin Med, 2018. DOI:10.3390/jcm7100357.
[51] Robb KP, Fitzgerald JC, Barry F, et al. Mesenchymal stromal cell therapy:progress in manufacturing and assessments of potency[J]. Cytotherapy, 2019, 21:289-306.
[52] DelaRosa O, Dalemans W, Lombardo E. Toll-like receptors as modulators of mesenchymal stem cells[J]. Front Immunol, 2012, 3:182.
[53] Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells:immune evasive, not immune privileged[J]. Nat Biotechnol, 2014, 32:252-260.
[54] Liang J, Zhang HY, Kong W, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion:a long-term retrospective study[J]. Stem Cell Res Ther, 2018, 9:312.
相关文献:
1.刘伯宁, 曹越, 卢加琪, 罗建辉.关于嵌合抗原受体修饰T细胞产品药学评价的思考[J]. 药学学报, 2018,53(10): 1637-1644